The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2020

Filed:

Mar. 21, 2018
Applicant:

Universität Zürich, Zürich, CH;

Inventors:

Daniel D. Pinschewer, Binningen, CH;

Lukas Flatz, Schaan, LI;

Andreas Bergthaler, Gmunden, AT;

Rolf Zinkernagel, Zumikon, CH;

Assignee:

UNIVERSITÄT ZÜRICH, Zurich, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/86 (2006.01); C12N 7/00 (2006.01); C07K 14/005 (2006.01); A61K 35/76 (2015.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 35/76 (2013.01); A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/525 (2013.01); A61K 2039/5256 (2013.01); C12N 2760/10032 (2013.01); C12N 2760/10034 (2013.01); C12N 2760/10043 (2013.01); C12N 2760/10061 (2013.01); C12N 2830/008 (2013.01); C12N 2840/203 (2013.01); C12N 2840/206 (2013.01); Y02A 50/412 (2018.01);
Abstract

The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases.


Find Patent Forward Citations

Loading…